Bristol-Myers Squibb Company (BMY)
| Market Cap | 84.19B |
| Revenue (ttm) | 45.53B |
| Net Income (ttm) | -6.15B |
| Shares Out | 2.03B |
| EPS (ttm) | -3.10 |
| PE Ratio | n/a |
| Forward PE | 6.00 |
| Dividend | $2.40 (5.78%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 11,304,258 |
| Open | 41.71 |
| Previous Close | 41.51 |
| Day's Range | 41.41 - 42.48 |
| 52-Week Range | 39.63 - 65.38 |
| Beta | 0.43 |
| Analysts | Hold |
| Price Target | 59.56 (+43.41%) |
| Earnings Date | Jul 26, 2024 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $59.56, which is an increase of 43.41% from the latest price.
News
Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80?
Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this per...
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyersSquibb--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients wit...
US FDA approves Bristol Myers' colorectal cancer therapy
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation, the health regulator's website s...
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyersSquibb--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab.
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024.
Bristol-Myers Squibb stock price forecast: Is the downtrend finally over?
Shares of Bristol-Myers Squibb Co (NYSE:BMY) have had a tumultuous journey since reaching its all-time high above $80 in December 2022. The stock has plummeted by over 50% and now trades in the low $4...
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive.
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBUR...
Why Bristol Myers Squibb Is A Top Socially Responsible Dividend Stock
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, as w...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastri...
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO24--Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or.
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--BMS' Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting.
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations.
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes
Treatment with Bristol Myers Squibb's immunotherapies Opdivo and Yervoy prior to surgery for patients whose skin cancer had spread to lymph nodes had better outcomes than those who did not get the dru...
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO24--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced.
US FDA allows use of Bristol's cell therapy for rare blood cancer
The U.S. Food and Drug Administration has allowed expanded use of Bristol Myers Squibb's cell therapy, Breyanzi, for an aggressive and rare type of blood cancer that affects the body's disease fightin...
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymph...
Bristol Myers Squibb Shares Cross 6% Yield Mark
In trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on the day....
2024 is being called ‘the year of the dividend.' These 5 stocks keep on giving.
Declining U.S. interest rates will boost yield-paying shares.
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Lin...
Menten AI Announces Completion of Research Collaboration with Bristol Myers Squibb
SAN FRANCISCO--(BUSINESS WIRE)-- #CADD--Menten AI, Inc., a biotechnology company with a generative AI platform for design and optimization of peptide macrocycles, today announced the completion of a p...